Tag: A166
Sorrento Announces Positive Results From Its License Partner, Kelun, on a...
A166 (ASCO Abstract #1024) is a third generation antibody drug conjugate (ADC) against HER2-positive breast cancer with Levena’s proprietary tubulin inhibitor Duo-5 toxin,...